DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Items 301–400 of 1,000
Multidrug-Resistant Bacteria in Hematology Patients: Emerging Threats
Tatarelli, P., & Mikulska, M. (2016) · Future Microbiology · doi:10.2217/fmb-2015-0014 · Cited by 31
Veillette, J. J., Winans, S. A., Forland, S. C., & Maskiewicz, V. K. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.08.010 · Cited by 29
Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis
Fujii, M., Karumai, T., Yamamoto, R., Kobayashi, E., Ogawa, K., Tounai, M., Lipman, J., & Hayashi, Y. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1750597 · Cited by 32
“achieve PD targets (50% fT > MIC) [9].”
BackgroundSelf-citationColin, P. J., Jonckheere, S., & Struys, M. M. R. F. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0643-8 · Cited by 28
“However, in the critically ill, these fixed dosing regimens frequently result in a significant proportion of patients not achieving the therapeutic target [11].”
BackgroundYadav, R., Bergen, P. J., Rogers, K. E., Kirkpatrick, C. M. J., Wallis, S. C., Huang, Y., Bulitta, J. B., Paterson, D. L., Lipman, J., Nation, R. L., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01679-19 · Cited by 28
“aeruginosa strains are particularly worrisome for critically ill patients, who not only commonly develop serious infections but also frequently display substantially altered pharmacokinetics (PK) compared with those of noncritically ill patients (8, 9).”
BackgroundSelf-citationHolmbom, M., Möller, V., Nilsson, L. E., Giske, C. G., Rashid, M.-U., Fredrikson, M. G., Hällgren, A., Hanberger, H., & Balkhed, Å. Ö. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230501 · Cited by 29
König, C., Both, A., Rohde, H., Kluge, S., Frey, O. R., Röhr, A. C., & Wichmann, D. (2021) · Antibiotics · doi:10.3390/antibiotics10060649 · Cited by 28
“with previous findings showing highly variable beta-lactam clearances and significant discrepancies of CKD-EPI eGFR and measured GFR in critically ill patients [23,24].”
ResultFéliu, C., Konecki, C., Candau, T., Vautier, D., Haudecoeur, C., Gozalo, C., Cazaubon, Y., & Djerada, Z. (2021) · Pharmaceuticals · doi:10.3390/ph14121214 · Cited by 31
Dilworth, T. J., Schulz, L. T., Micek, S. T., Kollef, M. H., & Rose, W. E. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000726 · Cited by 32
How to approach and treat VAP in ICU patients
Borgatta, B., & Rello, J. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-211 · Cited by 28
Self-citationBrinkmann, A., Röhr, A. C., Koeberer, A., Fuchs, T., Preisenberger, J., Krüger, W. A., & Frey, O. R. (2016) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-016-0213-5 · Cited by 31
Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges
Poulakou, G., Siakallis, G., Tsiodras, S., Arfaras-Melainis, A., & Dimopoulos, G. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1268052 · Cited by 29
Self-citationHaque, M. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i8.19468 · Cited by 33
Cies, J. J., Moore, W. S., Enache, A., & Chopra, A. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001497 · Cited by 28
Rules of anti-infection therapy for sepsis and septic shock
Zhou, X. Q., Su, L., Zhang, J., Liu, D., & Long, Y. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000101 · Cited by 29
Wu, C., Su, Y., Wu, K.-S., Wu, T., & Yang, C. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13301 · Cited by 27
Chahine, B. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02834-6 · Cited by 27
Fornasaro, S., Cialla‐May, D., Sergo, V., & Bonifacio, A. (2022) · Chemosensors · doi:10.3390/chemosensors10040128 · Cited by 27
Maimongkol, P., Yonwises, W., Anugulruengkitt, S., Sophonphan, J., Treyaprasert, W., & Wacharachaisurapol, N. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.052 · Cited by 27
Yow, H.-Y., Govindaraju, K., Lim, A. H., & Rahim, N. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.915355 · Cited by 29
Schatz, L. M., Brinkmann, A., Röhr, A. C., Frey, O. R., Greppmair, S., Weinelt, F. A., Zöller, M., Scharf, C., Hempel, G., & Liebchen, U. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00104-23 · Cited by 27
Practical Lessons on Antimicrobial Therapy for Critically Ill Patients
Cusack, R. A. F., Little, E., & Martín‐Loeches, I. (2024) · Antibiotics · doi:10.3390/antibiotics13020162 · Cited by 27
Grensemann, J., Busse, D., König, C., Roedl, K., Jäger, W. R., Jarczak, D., Iwersen‐Bergmann, S., Manthey, C., Kluge, S., Kloft, C., et al. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00666-8 · Cited by 31
“Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC‑based dose adjustment: facts and fables.”
BackgroundInfluentialAlarcia-Lacalle, A., Canut, A., Solinís, M. Á., Isla, A., & Rodríguez‐Gascón, A. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf096 · Cited by 26
Bjergum, M. W., Barreto, E. F., Scheetz, M. H., Rule, A. D., & Jannetto, P. J. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab036 · Cited by 27
Chiriac, U., Richter, D., Frey, O. R., Röhr, A. C., Helbig, S., Preisenberger, J., Hagel, S., Roberts, J. A., Weigand, M. A., & Brinkmann, A. (2021) · Antibiotics · doi:10.3390/antibiotics10060667 · Cited by 27
“Using the standard dosing regimen according to the Product Information is considered to have limited value in critical care as patients with sepsis and septic shock are likely to exhibit profound PK changes [9].”
BackgroundMethodResultInfluentialSelf-citationSuboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome*
Heggen, T. V. D., Dhont, E., Willems, J., Herck, I., Delanghe, J., Stove, V. V., Verstraete, A., Vanhaesebrouck, S., Paepe, P. D., & Cock, P. A. J. G. D. (2022) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002951 · Cited by 26
What’s new in therapeutic drug monitoring of antimicrobials?
Sjövall, F., Lanckohr, C., & Bracht, H. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07060-5 · Cited by 26
Bellouard, R., Deschanvres, C., Deslandes, G., Dailly, É., Asseray, N., Jolliet, P., Boutoille, D., Gaborit, B. J., & Grégoire, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00806-19 · Cited by 26
Dilworth, T. J., Leonard, S. N., Vilay, A. M., & Mercier, R.-C. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.027 · Cited by 26
“Moreover, many critically ill patients achieve lower than expected levels of β-lactams, likely due to physiologic changes that alter β-lactam PK parameters.(31) The results of our study should be generalizable, and it is possible that achieving a TZP free steady-state concentration of 27 mg/L would not have changed ou…”
ResultBrinkmann, A., Röhr, A. C., Frey, O. R., Krüger, W. A., Brenner, T., Richter, D., Bodmann, K. ‐., Kresken, M., & Grabein, B. (2018) · Der Anaesthesist · doi:10.1007/s00101-018-0512-8 · Cited by 25
High unbound flucloxacillin fraction in critically ill patients
Wallenburg, E., ter Heine, R., de Lange, D. W., van Leeuwen, H., Schouten, J. A., ten Oever, J., Kolwijck, E., Burger, D. M., Pickkers, P., Gieling, E. M., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab314 · Cited by 25
Smekal, A.-K., Furebring, M., Eliasson, E., & Lipcsey, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-25967-9 · Cited by 25
Coyne, A. J. K., Ghali, A. E., Lucas, K., Witucki, P., Rebold, N., Holger, D. J., Veve, M. P., & Rybak, M. J. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad034 · Cited by 27
“Additional prospective studies are warranted to examine this question, especially in a critically ill population that has previously demonstrated suboptimal β-lactam plasma concentrations even upon receipt of prolonged β-lactam infusions [40, 41].”
BackgroundVenuti, F., Romani, L., Luca, M. D., Tripiciano, C., Palma, P., Chiriaco, M., Finocchi, A., & Lancella, L. (2023) · Microorganisms · doi:10.3390/microorganisms11071798 · Cited by 28
“However, in cases of critically ill patients or when susceptibility data are pending, a more aggressive target (up to 100% ƒT > 4–5 × MIC) has shown to result in better outcomes [24,25].”
BackgroundCies, J. J., Moore, W. S., Calaman, S., Brown, M. D., Narayan, P., Parker, J., & Chopra, A. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1567 · Cited by 25
Miglis, C. M., Rhodes, N. J., Kuti, J. L., Nicolau, D. P., Wart, S. A. V., & Scheetz, M. H. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.04.023 · Cited by 25
Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape
Preijers, T., Muller, A. E., Abdulla, A., de Winter, B. C. M., Koch, B. C. P., & Sassen, S. D. T. (2024) · Drugs · doi:10.1007/s40265-024-02084-7 · Cited by 30
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Acute Medicine & Surgery · doi:10.1002/ams2.70037 · Cited by 27
Population pharmacokinetic model of cefazolin in total hip arthroplasty
Lanoiselée, J., Chaux, R., Hodin, S., Bourayou, S., Gibert, A., Philippot, R., Molliex, S. B., Zufferey, P. J., Delavenne, X., & Ollier, É. (2021) · Scientific Reports · doi:10.1038/s41598-021-99162-7 · Cited by 24
Barreto, E. F., Chang, J. H. T., Rule, A. D., Mara, K. C., Meade, L. A., Paul, J., Jannetto, P. J., Athreya, A. P., Scheetz, M. H., & for the BLOOM Study Group (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00810-23 · Cited by 24
“The high intra-and inter-patient variability in cefepime PK in sepsis leads to an unpredictable drug response (7, 8).”
BackgroundCarlier, M., Waele, J. J. D., Verstraete, A., & Stove, V. V. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0833 · Cited by 24
Yadav, R., Rogers, K. E., Bergen, P. J., Bulitta, J. B., Kirkpatrick, C. M. J., Wallis, S. C., Paterson, D. L., Nation, R. L., Lipman, J., Roberts, J. A., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00078-18 · Cited by 25
Self-citationMaarbjerg, S. F., Thorsted, A., Kristoffersson, A., Friberg, L. E., Nielsen, E. I., Wang, M., Brock, B., & Schrøder, H. D. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27654 · Cited by 24
Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients
Zembles, T. N., Schortemeyer, R. L., Kuhn, E. M., Bushee, G. M., Thompson, N. E., & Mitchell, M. L. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.2.187 · Cited by 24
Effects of i.v. push administration on β-lactam pharmacodynamics
Butterfield, J. M., & Burgner, K. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150883 · Cited by 24
Optimal use of β-lactams in neonates: machine learning-based clinical decision support system
Tang, B., Yao, B., Zhang, W., Zhang, X.-F., Fu, S., Hao, G., Zhou, Y., Sun, D., Liu, G., van den Anker, J. N., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105221 · Cited by 25
Desai, A., Ghosh, S., Sankaranarayanan, S., Bhatia, D. D., & Yadav, A. K. (2025) · Materials Advances · doi:10.1039/d5ma00487j · Cited by 26
Vooren, S. V., & Verstraete, A. (2021) · Biomedical Chromatography · doi:10.1002/bmc.5092 · Cited by 23
Rawson, T. M., Antcliffe, D. B., Wilson, R. C., Abdolrasouli, A., & Moore, L. S. P. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s390946 · Cited by 26
Karaba, S. M., Cosgrove, S. E., Lee, J. H., Fiawoo, S., Heil, E. L., Quartuccio, K. S., Shihadeh, K. C., & Tamma, P. D. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18234 · Cited by 27
Lheureux, O., Trépo, E., Hites, M., COTTON, F. J., Wolff, F., Surin, R., Créteur, J., Vincent, J., Gustot, T., Jacobs, F., et al. (2015) · Liver International · doi:10.1111/liv.13039 · Cited by 23
“Interestingly, use of an appropriate administration regimen (in terms of both dose and frequency) has been suggested as being at least as important as selection of an adequate antibacterial spectrum (5, 6).”
BackgroundSelf-citationStrich, J. R., & Kadri, S. S. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1696662 · Cited by 24
In-Water Antibiotic Dosing Practices on Pig Farms
Little, S., Woodward, A. P., Browning, G. F., & Billman‐Jacobe, H. (2021) · Antibiotics · doi:10.3390/antibiotics10020169 · Cited by 23
Tamme, K., Oselin, K., Kipper, K., Tasa, T., Metsvaht, T., Karjagin, J., Herodes, K., Kern, H., & Starkopf, J. (2015) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12629 · Cited by 23
Scaling beta‐lactam antimicrobial pharmacokinetics from early life to old age
Lonsdale, D., Baker, E. H., Kipper, K., Barker, C. I. S., Philips, B. J., Rhodes, A., Sharland, M., & Standing, J. F. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13756 · Cited by 23
“pharmacokinetic-pharmacodynamic targets and that this was associated with treatment failure [163].”
BackgroundSelf-citationAbdul-Aziz, M. H., Lipman, J., & Roberts, J. A. (2017) · Critical Care · doi:10.1186/s13054-017-1871-2 · Cited by 23
“The DALI study has reported significant variability in beta-lactam exposures in critically ill patients [5].”
BackgroundSelf-citationUnraveling the impact of therapeutic drug monitoring via machine learning for patients with sepsis
Ates, H. C., Alshanawani, A., Hagel, S., Cotta, M. O., Roberts, J. A., Dincer, C., & Ateş, C. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101681 · Cited by 28
Self-citationStitt, G. A., Morris, J. L., Schmees, L. R., Angelo, J., & Akcan‐Arikan, A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02006-18 · Cited by 22
Agyeman, A. A., Rogers, K. E., Tait, J. R., Bergen, P. J., Kirkpatrick, C. M. J., Wallis, S. C., Bulitta, J. B., Paterson, D. L., Lipman, J., Nation, R. L., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2191 · Cited by 23
Self-citationO’Jeanson, A., Larcher, R., Souder, C. L., Djebli, N., & Khier, S. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00709-w · Cited by 22
Zhao, Y., Lin, Q., Zhang, T., Zhen, S., Wang, J., Jiang, E., Mi, Y., Qiu, L., Han, M., Wang, J., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.08.037 · Cited by 22
Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?
Forsman, L. D., Kim, H. Y., Nguyen, T. A., & Alffenaar, J. C. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01346-7 · Cited by 22
“Due to emerging evidence, TDM is increasingly being used for antimicrobial drugs with a narrow therapeutic index to ensure maximum kill, that plasma drug concentrations corresponding to maximum kill or prevention of resistance is achieved [10].”
BackgroundAckerman, A., Zook, N. R., Siegrist, J. F., Brummitt, C. F., Cook, M. M., & Dilworth, T. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00066-20 · Cited by 21
“Interestingly, in the DALI study, ceftriaxone at a median dose of 2 g per day (interquartile range 2 to 4 g per day) had some of the highest levels of PK/PD target attainment of any -lactam studied (18).”
BackgroundCómitre, M. D. V., Cortellini, S., Cherlet, M., Devreese, M., Roques, B. B., Bousquet‐mélou, A., Toutain, P., & Pelligand, L. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.770202 · Cited by 21
Kim, Y. K., Kim, H. S., Park, S., Kim, H. I., Lee, S. H., & Lee, D. H. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac059 · Cited by 21
König, C., Grensemann, J., Czorlich, P., Schlemm, E., Kluge, S., & Wicha, S. G. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.017 · Cited by 21
Venugopalan, V., Hamza, M., Santevecchi, B. A., DeSear, K., Cherabuddi, K., Peloquin, C. A., & Al‐Shaer, M. H. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac171 · Cited by 21
Greibe, E., Moser, C. E., Bruun, N. E., & Hoffmann, E. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac195 · Cited by 21
Drug Dosing in Critically Ill Adult Patients with Augmented Renal Clearance
Hefny, F., Sambhi, S., Morris, C., Kung, J. Y. C., Stuart, A., & Mahmoud, S. H. (2022) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-022-00779-4 · Cited by 21
Kanji, S., Roger, C., Taccone, F. S., & Müller, L. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2858 · Cited by 21
Self-citationBarreto, E. F., Chang, J. H. T., Rule, A. D., Mara, K. C., Meade, L. A., Paul, J., Jannetto, P. J., Athreya, A. P., Scheetz, M. H., & For the BLOOM Study Group (2023) · Critical Care Explorations · doi:10.1097/cce.0000000000001011 · Cited by 21
Carlier, M., Roberts, J. A., Stove, V. V., Verstraete, A., Lipman, J., & Waele, J. J. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00409-15 · Cited by 21
“We simulated 30-min infusions for all antibiotics, as intermittent infusion remains the most common method of administration in ICUs (6).”
BackgroundMethodInfluentialSelf-citationChen, W., Zhang, D., Lian, W., Wang, X., Du, W., Zhang, Z., Guo, D., Zhang, X., Zhan, Q., & Li, P. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00385-20 · Cited by 21
Gijsen, M., Dreesen, E., Daele, R. V., Annaert, P., Debaveye, Y. A., Wauters, J., & Spriet, I. (2021) · Antibiotics · doi:10.3390/antibiotics10050557 · Cited by 21
Self-citationOptimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles
Hoo, G. S. R., Liew, Y. X., & Kwa, A. L. (2017) · Indian Journal of Medical Microbiology · doi:10.4103/ijmm.ijmm_17_278 · Cited by 25
“[50-53] There is no difference in mortality rates nor treatment failure rates between continuous infusion versus intermittent infusion although a lower risk of nephrotoxicity in those receiving continuous infusion has been demonstrated.[1-4] Continuous infusion of vancomycin is currently not routinely used in clinical…”
BackgroundAn, G., Creech, C. B., Wu, N., Nation, R. L., Gu, K., Nalbant, D., Jimenez‐Truque, N., Fissell, W. H., Rolsma, S. L., Patel, P. C., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01312-22 · Cited by 20
Ten reasons for the presence of pharmacy professionals in the intensive care unit
McKenzie, C., Spriet, I., & Hunfeld, N. (2024) · Intensive Care Medicine · doi:10.1007/s00134-023-07285-4 · Cited by 20
“ICU pharmacists lead trials in these domains in partnership with intensivists, which results in outstanding ICU research [11].”
Self-citationTranslational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s Perspective
Bissantz, C., Zampaloni, C., David‐Pierson, P., Dieppois, G., Guenther, A., Trauner, A., Winther, L., & Stubbings, W. J. (2024) · Antibiotics · doi:10.3390/antibiotics13010072 · Cited by 22
Abdul-Aziz, M. H., McDonald, C., McWhinney, B. C., Ungerer, J. P. J., Lipman, J., & Roberts, J. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014540610 · Cited by 20
“However, with standard bolus dosing (ie, 1-2 g every 4 hours), the requisite pharmacokinetic/pharmacodynamic (PK/PD) end point may not be achieved in critically ill patients.(6,7) Significant discordance in β-lactam PK is usually observed in this patient population, and the scenario may lead to subtherapeutic antibiot…”
BackgroundSelf-citationNon-invasive Drug Monitoring of β-Lactam Antibiotics Using Sweat Analysis—A Pilot Study
Brasier, N., Widmer, A. F., Osthoff, M. F., Mutke, M. R., Ieso, F. D., Brasier-Lutz, P., Wolfe, L. M., Aithal, V., Broeckling, C. D., Prenni, J. E., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00476 · Cited by 20
Pharmacokinetics of levetiracetam in neurosurgical ICU patients
Ong, C. L. J., Goh, P. S. J., Teo, M. M., Lim, T.-P., Goh, K. K. K., Ang, X. Y., Lim, L. J. K., Jamaludin, N. H. B., Ang, B. T., & Kwa, L. H. A. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.04.013 · Cited by 20
Ausman, S. E., Moreland-Head, L., Saleh, O. A., Jannetto, P. J., Rivera, C. G., Stevens, R. W., Wessel, R. J., Wieruszewski, P. M., Barreto, E. F., & For the BLOOM Study group (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1819 · Cited by 20
“tible to the pharmacokinetic derangements observed in the critically ill.(5,6) It is for this reason that BL have been identified as a viable drug class candidate for TDM.”
Chiriac, U., Richter, D., Frey, O. R., Röhr, A. C., Helbig, S., Hagel, S., Liebchen, U., Weigand, M. A., & Brinkmann, A. (2023) · Antibiotics · doi:10.3390/antibiotics12071112 · Cited by 19
“However, traditional antibiotic dosing is known to have repeatedly failed to attain PK/PD targets in previous studies in critically ill patients, which is associated with reduced chances of clinical cure, bacteriological eradication, and an increased risk of antimicrobial resistance [2,4,18,28].”
BackgroundResultInfluentialEmpirical decision-making for antimicrobial therapy in critically ill patients
Ippolito, M., & Cortegiani, A. (2023) · BJA Education · doi:10.1016/j.bjae.2023.09.001 · Cited by 19
Self-citationTakahashi, N., Kondo, Y., Kubo, K., Egi, M., Kano, K., Ohshima, Y., & Nakada, T. (2023) · Journal of Intensive Care · doi:10.1186/s40560-023-00699-8 · Cited by 19
“In such cases, the usual PK/PD-based dosing regimen may result in inadequate or excessive antibiotic concentrations, leading to poor clinical outcomes or organ damage such as kidney injury [12–14].”
BackgroundWilliams, P. G., Cotta, M. O., Tabah, A., Sandaradura, I., Kanji, S., Scheetz, M. H., Imani, S., Elhadi, M., Luque, S., Schellack, N., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107192 · Cited by 19
Self-citationJonckheere, S., Neve, N. D., Beenhouwer, H. D., Berth, M., Vermeulen, A., Bocxlaer, J. V., & Colin, P. J. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw171 · Cited by 19
Veillette, J. J., Truong, J. Q., & Forland, S. C. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1840 · Cited by 19
Gustinetti, G., Cangemi, G., Bandettini, R., & Castagnola, E. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1377909 · Cited by 19
Dhaese, S. A. M., Colin, P. J., Willems, H., Heffernan, A. J., Gadeyne, B., Vooren, S. V., Depuydt, P. O., Hoste, E. A. J., Stove, V. V., Verstraete, A., et al. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.08.024 · Cited by 20
Self-citationde Oliveira, M. S., Machado, A. S., Mendes, E. T., Chaves, L., Neto, L. V. P., da Silva, C. V., Santos, S. R. C. J., Sanches, C., Macedo, E. M., & Levin, A. S. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.02.011 · Cited by 19
Hughes, S., Heard, K. L., Mughal, N., & Moore, L. S. P. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac080 · Cited by 19
Roberts, J. A., Choi, G. Y. S., Joynt, G. M., Paul, S. K., Deans, R., Peake, S., Cole, L., Stephens, D. P., Bellomo, R., Turnidge, J. D., et al. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1421-6 · Cited by 19
Self-citationAdäquate Antiinfektivatherapie: Bedeutung der individuellen Dosierung und Applikation
Brinkmann, A., Röhr, A. C., Koeberer, A., Fuchs, T., Krüger, W. A., König, C., Richter, D., Weigand, M. A., & Frey, O. R. (2018) · Der Anaesthesist · doi:10.1007/s00101-018-0443-4 · Cited by 19
“Es gibt inzwischen Hinweise aus der Literatur, dass eine prolongierte [42] und kontinuierliche Applikation von β-Lactam-Antibiotika nicht nur das Erreichen von PK/PD-Zielen erleichtert [8, 10] und die Gewebepenetration verbessert [13], sondern darüber hinaus auch die Sterblichkeit, v.”
MethodInfluentialKorake, S., Pawar, A., Surywanshi, S., Bothiraja, C., & Pawar, A. (2020) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2020v12i10.38638 · Cited by 18
Chongcharoenyanon, T., Wacharachaisurapol, N., Anugulruengkitt, S., Maimongkol, P., Anunsittichai, O., Sophonphan, J., Chatsuwan, T., & Puthanakit, T. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.044 · Cited by 18
Al‐Shaer, M. H., Goutelle, S., Santevecchi, B. A., Shoulders, B. R., Venugopalan, V., Cherabuddi, K., Liu, J., Kiel, P. J., Roberts, J. A., Sime, F. B., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02046-21 · Cited by 18
“Reed (8) UF Health Roberts (7) Sime (9) Whited (10)”
BackgroundMethodSelf-citationLaiseca, L. B., Marco‐Ariño, N., Trocóniz, I. F., Grau, S., Campillo, N., García‐González, X., Padilla, B., Fernández, S. N., Slöcker-Barrio, M., & Santiago, M. J. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.031 · Cited by 18
Cutuli, S. L., Cascarano, L., Lazzaro, P., Tanzarella, E. S., Pintaudi, G., Grieco, D. L., PASCALE, G. D., & Antonelli, M. M. (2023) · Microorganisms · doi:10.3390/microorganisms11020473 · Cited by 20
““standard” dosing regimens based on empiric rules in critically ill septic patients were associated with inadequate antimicrobial exposure, which was mostly due to sepsisassociated homeostatic alterations affecting the drug distribution and clearance [3,6,7], and implied an increased risk of worse clinical outcomes [3…”
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.